Important Deadline Approaches for Soleno Therapeutics Investors in Class Action Suit

Important Deadline Approaches for Soleno Therapeutics Investors

Faruqi & Faruqi, LLP, a prominent national securities law firm, is alerting investors in Soleno Therapeutics, Inc. about the impending deadline to join a securities class action lawsuit. This deadline is set for May 5, 2026, and it presents a crucial opportunity for affected investors to assert their rights.

With a track record of recovering hundreds of millions of dollars for investors, Faruqi & Faruqi is currently assessing potential claims against Soleno Therapeutics. This action arises after the firm received significant information regarding possible misrepresentations made by Soleno and its executives during the company's clinical trials involving the drug candidate DCCR.

The allegations against Soleno state that the company failed to disclose serious safety concerns raised in the Phase 3 clinical trial program. These concerns included issues related to excess fluid retention among trial participants, which were reportedly downplayed or obscured by the company. Such actions could potentially lead to higher safety risks that were not accurately communicated to stakeholders.

The situation escalated with a critical report published by Scorpion Capital LLC on August 15, 2025, which scrutinized the drug's safety and efficacy. Following this report, Soleno's stock price sharply declined, reflecting market apprehension over the reported safety issues. Specifically, in just two trading days, the stock price fell nearly 12%, a clear indicator of investor reaction to the troubling news.

Further compounding these issues, the company disclosed that a patient had tragically died after taking DCCR, prompting another significant decline in stock value—approximately 19% over two days. As of November 4, 2025, amid failing expectations for DCCR, shares plummeted by nearly 27% in a single day after revealing financing struggles and growing concerns within the Prader-Willi syndrome community.

Faruqi & Faruqi emphasizes that any investor who purchased or obtained securities in Soleno between March 26, 2025, and November 4, 2025, may have legal grounds to participate in the upcoming class action and potentially serve as a lead plaintiff. The lead plaintiff is typically one with the most significant financial interest in the outcome of the case and plays a key role in guiding the litigation process.

For investors who wish to discuss their legal rights or gather more information about the case, they are encouraged to contact Josh Wilson, a Senior Partner at Faruqi & Faruqi, directly via telephone. The firm is also open to hearing from whistleblowers, former employees, or anyone else with pertinent information related to the company’s alleged conduct.

In conclusion, the class action against Soleno Therapeutics represents a pivotal moment for investors to seek justice and recovery for their losses. With the deadline fast approaching, affected investors are urged to act promptly to explore their options and understand their rights under the law. For more details, refer to Faruqi & Faruqi's page for Soleno Therapeutics.

This legal proceeding showcases the commitment to transparency and accountability in the pharmaceutical sector, underscoring the importance of accurate disclosures to investors—an essential aspect of maintaining trust in the healthcare industry.